Laurus Labs Ltd vs Medicamen Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 13, 2026

Key Highlights

The Latest Trading Price of Laurus Labs Ltd is ₹ 1394 as of 12 Jun 15:30 . The P/E Ratio of Laurus Labs Ltd changed from 19.8 on March 2021 to 60.3 on March 2026 . This represents a CAGR of 20.40% over 6 yearsThe P/E Ratio of Medicamen Biotech Ltd changed from 53.8 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Laurus Labs Ltd changed from ₹ 19427 crore on March 2021 to ₹ 53545 crore on March 2026 . This represents a CAGR of 18.41% over 6 yearsThe Market Cap of Medicamen Biotech Ltd changed from ₹ 652.37 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Laurus Labs Ltd for the Mar '26 is ₹ 1823 crore as compare to the Dec '25 revenue of ₹ 1784 crore. This represent the growth of 2.2% The revenue of Medicamen Biotech Ltd for the Mar '26 is ₹ 62.38 crore as compare to the Dec '25 revenue of ₹ 47.44 crore. This represent the growth of 31.49% The ebitda of Laurus Labs Ltd for the Mar '26 is ₹ 523.91 crore as compare to the Dec '25 ebitda of ₹ 485.97 crore. This represent the growth of 7.81% The ebitda of Medicamen Biotech Ltd for the Mar '26 is ₹ 7.18 crore as compare to the Dec '25 ebitda of ₹ 4.91 crore. This represent the growth of 46.23% The net profit of Laurus Labs Ltd changed from ₹ 12.21 crore to ₹ 281.91 crore over 8 quarters. This represents a CAGR of 380.50% The net profit of Medicamen Biotech Ltd changed from ₹ 0.8 crore to ₹ 4.45 crore over 8 quarters. This represents a CAGR of 135.85% The Dividend Payout of Laurus Labs Ltd changed from 11.22 % on March 2021 to 14.58 % on March 2026 . This represents a CAGR of 4.46% over 6 yearsThe Dividend Payout of Medicamen Biotech Ltd changed from 9.78 % on March 2021 to 0 % on March 2026 . This represents a CAGR of -100.00% over 6 years .

About Laurus Labs Ltd

Laurus Labs Limited was originally incorporated as 'Laurus Labs Private Limited' on September 19, 2005 at Hyderabad, Andhra Pradesh, India as a private limited company.
The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited on February 12, 2007.
Subsequently the name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore on July 19, 2007.
Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited on July 24, 2007.
Subsequently, company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited on August 16, 2016. Laurus Labs is a science-led, fully integrated pharmaceutical and biotechnology manufacturing company with a leadership position in generic active pharmaceutical ingredients (APIs) in selected high-growth therapeutic areas of anti-retrovirals (ARVs), Hepatitis C and Oncology.

About Medicamen Biotech Ltd

A diversified enterprise, Medicamen Biotech Limited (MBL) is a research-led pharmaceutical company involved in developing, manufacturing and marketing of finished dosage formulations for domestic as well as international markets.
The Company has presence over 35+ countries.
Its offerings include Finished Dosage Forms (FDF's) to African countries. In India, MBL is among the leading companies in oncology segment with its own sales force and a branding team that has helped garner a strong foothold in the domestic market.
MBL has three pharma formulation facilities including two in Haridwar (Uttarakhand), one in Bhiwadi (Rajasthan).
The Company manufactures products across various therapeutic categories including Pain Management, Cough & Cold, Cardiovascular & Central Nervous System, Anti-Diabetic, Gastrointestinal, Anti-Allergic among others.

FAQs for the comparison of Laurus Labs Ltd and Medicamen Biotech Ltd

Which company has a larger market capitalization, Laurus Labs Ltd or Medicamen Biotech Ltd?

Market cap of Laurus Labs Ltd is 75,316 Cr while Market cap of Medicamen Biotech Ltd is 311 Cr

What are the key factors driving the stock performance of Laurus Labs Ltd and Medicamen Biotech Ltd?

The stock performance of Laurus Labs Ltd and Medicamen Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Laurus Labs Ltd and Medicamen Biotech Ltd?

As of June 13, 2026, the Laurus Labs Ltd stock price is INR ₹1394.1. On the other hand, Medicamen Biotech Ltd stock price is INR ₹229.45.

How do dividend payouts of Laurus Labs Ltd and Medicamen Biotech Ltd compare?

To compare the dividend payouts of Laurus Labs Ltd and Medicamen Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.